Summary: In a phase 2a crossover trial in type 1 diabetes, the GPR119 agonist MBX-2982 did not improve glucagon or other counterregulatory responses to experimental hypoglycemia, despite evidence of target engagement, indicating GPR119 agonists are unlikely to mitigate hypoglycemia risk.
PICO Summary
| Element | Detail |
|---|---|
| Population | 18 adults (aged 20–60) with type 1 diabetes; phase 2a, double-masked crossover. |
| Intervention | MBX-2982 (GPR119 agonist) 600 mg daily for 14 days. |
| Comparison | Placebo, with 2-week washout; hyperinsulinemic euglycemic-hypoglycemic clamp and mixed-meal test. |
| Outcome | No significant difference in maximum glucagon, glucagon AUC, or incremental AUC versus placebo, and no effect on epinephrine, norepinephrine, pancreatic polypeptide, free fatty acids, or endogenous glucose production. GLP-1 during the meal test was 17% higher (target engagement confirmed). |
Expert Commentary
This is a clean negative trial, and it is important to say so plainly, because the earlier version of this page had it backwards. The hypothesis was elegant, that activating GPR119 might restore the glucagon counterregulatory response lost in type 1 diabetes, and the preclinical rationale was reasonable. But in patients the drug simply did not deliver: glucagon responses to clamp-induced hypoglycemia were no different from placebo, and nor were the adrenergic or glucose-production responses. The one positive, a 17% rise in meal-stimulated GLP-1, confirms the drug was actually engaging its target, which makes the absence of any counterregulatory benefit all the more informative, the approach was tested fairly and failed. The authors’ own conclusion, that GPR119 agonists are unlikely to help hypoglycemia risk in type 1 diabetes, is the honest takeaway. Can I use this with my patients? Not in the sense of a new therapy, because there is none here. Its value is in steering the field away from a dead end and reinforcing that hypoglycemia protection in type 1 diabetes still rests on CGM, automated insulin delivery, awareness training, and access to rescue glucagon. Negative trials like this prevent wasted hope and effort.
References
Bilal A, Casu A, Yi F, et al. A randomized controlled, double-masked, crossover study of a GPR119 agonist on glucagon counterregulation during hypoglycemia in type 1 diabetes. Diabetes. 2025;74(7):1262–1272. doi:10.2337/db25-0096